YOLFTbeta
Royalty Pharma Plc

Royalty Pharma Plc

RPRX · NASDAQ · Healthcare / Biotechnology

69.31USD+0.34 (+0.49%)

Price History

Full chart

Market Stats

Previous Close68.97
Open68.77
Day Range68.14 – 69.43
52-Week Range35.34 – 66.29
Volume2.95M
Market Cap37.46B
P/E (TTM)34.48
Forward P/E33.33
EPS1.88
Dividend Yield1.45%
Beta0.41
50-Day Avg60.06
200-Day Avg52.96

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Pablo Legorreta
  • Employees100
  • Headquarters110 East 59th Street, New York, NY, United States, 10022, USA
  • Websitehttps://www.royaltypharma.com

Leadership

  • Mr. Pablo LegorretaFounder, Chairman of the Board & CEO · b. 1963
  • Mr. Terrance P. CoyneExecutive VP & CFO
  • Mr. Christopher HiteChairman of Partnering & Investments · b. 1967
  • Dr. Marshall Jonathan Urist M.D., Ph.D.Head of Research & Investments · b. 1976
  • Mr. Greg ButzExecutive Vice President of Partnering & Investments
  • Mr. Eric Cornelius SchneiderSenior VP & Chief Technology Officer
  • Dr. James Folmar Reddoch Ph.D.Executive VP of Investments & Chief Scientific Officer · b. 1970
  • Mr. George Grofik C.F.A., CPASenior VP and Head of Investor Relations & Communications
  • Mr. Arthur Richard McGivern J.D.Executive VP of Investment & Chief Legal Officer · b. 1975
  • Ms. Molly SawayaExecutive VP & Head of Human Capital

Financials

Income Statement

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.35M2.33M4.54M595.00K118.00K4.00K----244.00K---01.65B1.88B1.60B1.79B1.81B2.12B2.29B2.24B2.35B2.26B2.38B
Growth (%)--0.68%+94.56%-86.90%-80.17%-96.61%----------+13.62%-14.89%+12.33%+1.08%+16.98%+7.87%-2.28%+5.24%-3.86%+5.06%
Cost of Revenue6.86M3.67M7.91M4.27M3.64M8.02M--25.59M26.44M5.10M---00033.27M135.96M1.02B230.84M452.84M904.24M560.66M732.46M3.85M
Gross Profit--------------01.65B1.88B1.60B1.79B1.81B2.12B2.29B2.24B2.35B2.26B2.38B
Gross Margin---------------100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense--------------32.54M858.14M1.15B658.24M430.45M-808.92M526.95M858.75M1.93B862.40M971.13M818.67M
Operating Income---------------32.54M794.28M722.87M939.69M1.36B2.62B1.60B1.43B307.06M1.49B1.29B1.56B
Operating Margin---------------48.07%38.50%58.81%76.02%144.59%75.17%62.49%13.73%63.37%57.10%65.58%
EBITDA---------------862.44M1.07B1.62B1.83B2.75B1.88B1.43B423.69M1.89B1.56B1.64B
EBITDA Margin---------------52.19%56.94%101.62%102.02%151.79%88.68%62.47%18.94%80.15%68.76%68.78%
Net Income---------------32.53M581.43M565.91M1.21B1.38B2.35B975.04M619.73M42.83M1.13B858.98M770.95M
Net Income Margin---------------35.19%30.14%75.72%76.76%129.45%45.94%27.07%1.91%48.20%37.95%32.42%
R&D4.50M3.03M6.42M2.16M2.47M6.10M11.91M12.42M22.57M23.06M2.90M8.68M13.34M22.91M27.11M98.38M91.02M117.87M392.61M83.04M26.29M200.08M177.11M52.00M2.00M452.00M
R&D as % of Total Revenue191.20%129.68%141.32%363.19%2094.07%152525.00%----1190.16%----5.95%4.85%7.38%21.87%4.58%1.24%8.74%7.92%2.21%0.09%19.01%
Interest Expense000000000000000224.42M238.91M247.34M279.96M268.57M157.06M166.14M187.96M187.19M225.51M307.66M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%----0.00%----13.58%12.73%15.48%15.60%14.80%7.40%7.26%8.40%7.95%9.96%12.94%

Balance Sheet

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets40.37M36.91M27.37M24.03M6.61M17.68M7.85M27.60M22.60M2.96M4.46M6.06M26.83M78.98M46.94M10.82B10.48B11.37B11.37B12.45B21.10B17.52B16.81B16.38B18.22B19.62B
Total Liabilities9.31M6.34M519.00K541.00K614.00K727.00K4.06M3.54M6.99M2.40M1.30M1.40M3.80M3.55M2.92M6.12B6.02B6.90B6.82B6.31B6.12B7.27B7.29B6.30B7.88B9.91B
Total Equity31.06M30.57M26.85M23.49M5.99M16.95M3.79M24.06M15.61M562.00K3.17M4.67M23.03M75.42M44.02M4.68B4.45B4.46B4.49B6.11B14.97B10.25B5.63B6.53B6.95B6.48B
Cash2.51M1.52M8.68M20.95M736.00K2.17M1.14M1.78M19.47M1.89M2.96M4.57M24.21M75.81M46.62M1.72B1.67B1.38B1.92B246.20M1.01B1.54B1.71B477.01M929.03M618.70M
Total Debt---------------5.99B5.90B6.80B6.52B6.24B6.10B13.99B7.12B6.14B7.61B8.95B
Net Debt---------------4.27B4.22B5.42B4.60B5.99B4.81B5.56B5.41B5.66B6.68B8.33B

Cash Flow

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--8.45M11.15M-----------29.33M-25.33M-15.58M1.42B1.62B1.67B2.03B2.02B2.14B2.99B2.77B2.49B
Investing Cash Flow4.38M1.62M-1.16M----23.55M---------1.59B303.42M-2.15B-2.76B-1.87B-1.03B-2.07B-2.68B-1.61B
Financing Cash Flow139.00K50.00K27.00K--18.86M241.00K33.09M15.88M5.00M6.39M11.71M33.75M76.95M147.00K102.00K2.88M-123.25M-1.38B-1.19B1.49B385.11M-944.86M-2.15B361.14M-1.19B
Capital Expenditure57.00K1.00K49.00K021.00K8.00K64.00K6.00K4.00K07.00K15.00K30.00K63.00K0002.29B269.59M1.72B2.20B523.00K2.04B2.12B00
Free Cash Flow-----------------1.42B1.62B1.67B4.23B2.02B4.19B2.99B2.77B2.49B
Dividends Paid-----------------735.17M814.36M739.28M397.00M285.18M333.32M358.33M376.46M378.25M
FCF to OCF-----------------100.00%100.00%100.00%207.98%100.03%195.20%100.00%100.00%100.00%
Dividend Paid to FCF-----------------51.83%50.32%44.34%9.38%14.13%7.96%11.99%13.60%15.19%

Earnings

Report DateDec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Jun 17, 2020Aug 12, 2020Nov 10, 2020Feb 17, 2021May 11, 2021Aug 11, 2021Nov 10, 2021Feb 15, 2022May 5, 2022Aug 4, 2022Nov 8, 2022Feb 15, 2023May 9, 2023Aug 8, 2023Nov 8, 2023Feb 15, 2024May 9, 2024Aug 8, 2024Nov 6, 2024Feb 11, 2025May 8, 2025Aug 6, 2025Nov 5, 2025Feb 11, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate-0.17-0.14-0.22-0.280.520.600.590.700.650.710.700.780.720.780.711.461.270.810.771.000.980.970.931.050.951.031.111.331.181.271.18
EPS Actual-0.16-0.22-0.08-0.053.940.610.650.700.670.710.730.800.600.790.731.561.600.840.791.520.980.961.041.151.061.141.171.471.301.32-
Surprise5.88%-57.14%63.64%82.14%657.69%1.67%10.17%0.00%3.08%0.00%4.29%2.56%-16.67%1.28%2.82%6.85%25.98%3.70%2.60%52.00%0.00%-1.03%11.83%9.52%11.58%10.68%5.41%10.53%10.17%3.94%-
Timing----After-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap37.46B
Enterprise Value36.10B
Trailing P/E34.48
Forward P/E33.33
PEG Ratio1.52
Price / Sales14.77
Price / Book4.25
EPS1.88
Book Value15.33
Revenue (TTM)2.54B
Gross Profit (TTM)2.43B
EBITDA1.56B
Profit Margin32.02%
Operating Margin19.75%
Return on Equity13.97%
Return on Assets5.09%
Shares Outstanding445.28M
Shares Float417.58M
Beta0.41
Dividend Yield1.45%
Dividend Rate0.94
Payout Ratio17.87%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 65.38
  • Strong Buy
    5
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
88.27%
Insiders
6.49%
Retail / Other
5.24%

Top Institutional Holders

  • Morgan Stanley - Brokerage Accounts
    42.93M9.64%
  • Capital Research & Mgmt Co - Division 3
    35.27M7.92%
  • BlackRock Inc
    27.83M6.25%
  • FMR Inc
    24.51M5.51%
  • State Street Corp
    12.34M2.77%
  • T. Rowe Price Associates, Inc.
    11.19M2.51%
  • Swedbank AB
    10.73M2.41%
  • Baillie Gifford & Co Limited.
    10.02M2.25%
  • Capital World Investors
    9.52M2.14%
  • Geode Capital Management, LLC
    8.06M1.81%
  • Caledonia (Private) Investments Pty Ltd
    5.78M1.30%
  • NORGES BANK
    5.34M1.20%
  • Vanguard Capital Management, LLC
    4.83M1.08%
  • Northern Trust Corp
    4.72M1.06%
  • Royal London Asset Management Ltd
    4.32M0.97%

Top Fund Holders

  • American Funds New Perspective A
    19.34M4.34%
  • American Funds Capital Inc Bldr A
    7.43M1.67%
  • American Funds Growth Fd of Amer A
    6.75M1.52%
  • Morgan Stanley Inst Growth I
    4.91M1.10%
  • MS INVF US Advantage I
    4.80M1.08%

Dividends

20264×
0.23Nov 13, 20260.23Aug 14, 20260.23May 15, 20260.23Feb 20, 2026
20254×
0.22Nov 14, 20250.22Aug 15, 20250.22May 16, 20250.22Feb 21, 2025
20244×
0.21Nov 15, 20240.21Aug 16, 20240.21May 16, 20240.21Feb 15, 2024
20234×
0.20Nov 16, 20230.20Aug 17, 20230.20May 18, 20230.20Feb 15, 2023
20224×
0.19Nov 17, 20220.19Aug 18, 20220.19May 19, 20220.19Feb 17, 2022
20214×
0.17Nov 18, 20210.17Aug 19, 20210.17May 19, 20210.17Feb 18, 2021